ALDERLEY PARK, Cheshire - Infex Therapeutics Holdings plc, a UK-based anti-infectives specialist, in partnership with Justus-Liebig-University Giessen (JLU) in Germany, has been awarded a £1 ...

ALDERLEY PARK, Cheshire, U.K. - Infex Therapeutics has entered into an exclusive license agreement with Venus Remedies Ltd, an Indian pharmaceutical company, to further develop and commercialize ...

ALDERLEY PARK, Cheshire, U.K. - Infex Therapeutics has entered into an exclusive license agreement with Venus Remedies Ltd, an Indian pharmaceutical company, to further develop and commercialize MET-X ...

英国柴郡奥德利园 - Infex Therapeutics与印度制药公司Venus Remedies达成独家许可协议，将在印度市场进一步开发和商业化MET-X。MET-X是一种旨在对抗革兰氏阴性肠杆菌科耐药感染的治疗方案。 Venus Remedies将出资并在印度开展MET-X与抗生素美罗培南联合用药的I期临床试验。

英国柴郡奥德利园区 - 英国抗感染专业公司Infex Therapeutics Holdings plc与德国吉森-尤斯图斯-李比希大学(JLU)合作，获得了来自PACE(抗菌药物临床效果路径)的100万英镑资助。该资助旨在推进一类新型抗菌药物BamA抑制剂的开发，这种药物专门针对多重耐药(MDR)革兰氏 ...

Venus Remedies announced a strategic partnership with UK-based Infex Therapeutics on Tuesday to develop MET-X, a groundbreaking metallo-beta-lactamase inhibitor targeting drug-resistant gram-negative ...

Infex will receive licence fee payments upon signature and completion of near-term milestones and tiered double-digit royalty payments on net sales of MET-X/meropenem in India by Venus.

Venus Remedies shares rose 4.2 per cent in Tuesday's trade on BSE, logging an intraday high at Rs 320 per share. The counter saw buying after the company signed an exclusive license agreement with ...